Hypercalcemia of Malignancy Management

Algorithm Steps

1. ▶

   Start

   Hypercalcemia of Malignancy

   Elevated calcium in setting of known/suspected malignancy

   1. ◆

      Decision

      Assess Severity

      Corrected calcium or ionized calcium

      • Mild: Corrected Ca 10.5-12 mg/dL (2.6-3.0 mmol/L)
      • Moderate: Corrected Ca 12-14 mg/dL (3.0-3.5 mmol/L)
      • Severe: Corrected Ca >14 mg/dL (>3.5 mmol/L)
      • Correction: Add 0.8 mg/dL for each 1 g/dL albumin below 4
      1. ●

         Action

         Clinical Manifestations

         'Stones, bones, groans, moans, and psychic overtones'

         • GI: Nausea, vomiting, constipation, anorexia, pancreatitis
         • Neuro: Confusion, lethargy, weakness, coma
         • Cardiac: Shortened QT, bradycardia, arrhythmias
         • Renal: Polyuria, polydipsia, nephrolithiasis, AKI
         • Musculoskeletal: Bone pain, weakness
         1. ●

            Action

            1. IV Fluid Resuscitation

            First-line treatment for all patients

            • 0.9% Normal Saline 200-300 mL/hr initially
            • Target: 3-6 L in first 24 hours
            • Goal: Restore volume, enhance renal calcium excretion
            • Adjust for cardiac/renal status
            • Monitor for fluid overload
            1. ◆

               Decision

               Severity-Based Treatment

               Additional therapy based on calcium level

               1. ●

                  Action

                  SEVERE (Ca >14 mg/dL)

                  Calcitonin + IV bisphosphonate or denosumab

                  • Calcitonin 4 IU/kg IM/SubQ q12h for 48-72h
                  • Provides rapid (but transient) calcium lowering
                  • Tachyphylaxis develops in 48-72h
                  • PLUS long-acting agent (see next)
                  1. ◆

                     Decision

                     2. Choose: IV Bisphosphonate vs Denosumab

                     Endocrine Society suggests denosumab over IV BP

                     1. ●

                        Action

                        IV Bisphosphonate

                        Zoledronic acid preferred

                        • Zoledronic acid 4 mg IV over 15 min (preferred)
                        • OR Pamidronate 60-90 mg IV over 2-4 hours
                        • Onset: 2-4 days, Duration: 2-4 weeks
                        • Adjust for renal function (CrCl <30: avoid zoledronic)
                        • Can repeat in 7 days if needed
                        1. ●

                           Action

                           Refractory/Recurrent HCM

                           Options for treatment-resistant cases

                           • If on bisphosphonate: Switch to denosumab
                           • If on denosumab: Add or switch to bisphosphonate
                           • Consider calcimimetic (cinacalcet) for parathyroid carcinoma
                           • Glucocorticoids for calcitriol-mediated HCM
                           • Dialysis for severe, refractory cases
                           1. ●

                              Action

                              3. Monitoring

                              Close follow-up during treatment

                              • Calcium: q6-12h initially, then daily
                              • Creatinine, electrolytes: daily
                              • Phosphorus: may decrease with bisphosphonates
                              • Watch for hypocalcemia (especially with denosumab)
                              • Fluid balance
                              1. ✓

                                 Outcome

                                 Calcium Controlled

                                 Continue cancer treatment, monitor for recurrence

                              2. ⚠

                                 Warning

                                 Palliative Considerations

                                 End-stage malignancy, comfort care

                                 • HCM may be terminal event
                                 • Discuss goals of care
                                 • Symptom management focus
                     2. ●

                        Action

                        Denosumab

                        RANK-L inhibitor, suggested over bisphosphonates

                        • Denosumab 120 mg SubQ
                        • Onset: 2-4 days, Duration: 4 weeks
                        • Safe in renal impairment (no dose adjustment)
                        • Can give additional doses on days 8, 15, 29 for refractory cases
                        • CAUTION: Rebound hypercalcemia after discontinuation
                     3. ⚠

                        Warning

                        ⚠️ Calcitriol-Mediated HCM

                        Lymphoma, granulomatous disease

                        • First-line: Glucocorticoids (prednisone 20-40 mg/day)
                        • Reduces calcitriol production by macrophages
                        • Add bisphosphonate/denosumab if glucocorticoids insufficient
               2. ●

                  Action

                  MODERATE (Ca 12-14 mg/dL)

                  IV bisphosphonate or denosumab

                  • Skip calcitonin unless very symptomatic
                  • Proceed directly to bisphosphonate or denosumab
               3. ●

                  Action

                  MILD (Ca 10.5-12 mg/dL)

                  Fluids, may not need additional therapy

                  • IV fluids often sufficient
                  • Consider bisphosphonate/denosumab if symptomatic
                  • Treat underlying malignancy